Sanguine Corp. (fka SGUI)

[manny21]

PASADENA, Calif., Jan 30, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC - News) is pleased to announce that it will be opening an
office in West Chester, Pennsylvania, to expand its operations and to secure
east coast representation. The West Chester office will house Sanguine's newly
formed life sciences division. The focus of the life sciences division is to
advance SGNC through the development and acquisition of projects and
technologies that will produce revenue for the Company. The West Chester office
will also be increasing the current efforts to commercialize Sanguine's flagship
product, PHER-02.

West Chester is located just outside of Philadelphia, Pennsylvania, an hour from
Baltimore Maryland and an hour and a half from New York City and Washington D.C.
This ideal location is going to give Sanguine much easier access to some of the
largest cities, hospitals and universities in the country.

David Nelson, Sanguine's CFO, said, "The opening of this new office is an
integral component in our strategy to advance Sanguine. We anticipate many good
things coming from this satellite office."

About Sanguine

Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on
the development of an oxygen-carrying synthetic substitute for human red blood
cells and various other areas requiring oxygen profusion. The company is
developing a synthetic red blood cell product, PHER-O2 that consists of
perfluoro-decalin molecules or synthetic red blood cells, purified water, and a
synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is
under Phase II clinical trials and has oxygen-carrying capacity.

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: [e-mail], or visit:
www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation